Ignite Creation Date:
2024-05-06 @ 4:07 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04874077
Status:
COMPLETED
Last Update Posted:
2022-07-06
First Post:
2021-04-30
Brief Title:
Using Voice Biomarkers to Predict the Likelihood of Major Depressive Disorder
Sponsor:
Kintsugi Mindful Wellness Inc
Organization:
Kintsugi Mindful Wellness Inc
Study Overview
Official Title:
Using Voice Biomarkers to Predict the Likelihood of Major Depressive Disorder A Multi-Site Fully Remote E-Clinical Validation Study
Status:
COMPLETED
Status Verified Date:
2022-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Major Depressive Disorder MDD is the leading cause of disability worldwide Depression and anxiety disorders are among the most prevalent of all mental disorders with an estimated annual prevalence of 97 and 181 respectively
It has been known for the last 100 years that depression and anxiety both likely affect vocal acoustic properties In 1921 Emil Kraepelin characterized depressed patients voices as having a lower pitch lower volume lower rate of speech more monotony of prosody as well as more hesitations stuttering and whispering
Mechanistically it is possible that the neural circuitry involved in the pathophysiology of mood and anxiety disorders impinge upon the neural circuit involved in speech production affecting qualities that include rate prosody speech latency and other paralinguistic features Thus acoustic features of speech may be one of the more readily accessible biomarkers for these conditions
Given this understanding the investigators sought to develop a passive vocal biomarker instrument for depression and anxiety screening that could markedly expand access as well as standardize the quality of screening in primary care settings
It has been known for the last 100 years that depression and anxiety both likely affect vocal acoustic properties In 1921 Emil Kraepelin characterized depressed patients voices as having a lower pitch lower volume lower rate of speech more monotony of prosody as well as more hesitations stuttering and whispering
Mechanistically it is possible that the neural circuitry involved in the pathophysiology of mood and anxiety disorders impinge upon the neural circuit involved in speech production affecting qualities that include rate prosody speech latency and other paralinguistic features Thus acoustic features of speech may be one of the more readily accessible biomarkers for these conditions
Given this understanding the investigators sought to develop a passive vocal biomarker instrument for depression and anxiety screening that could markedly expand access as well as standardize the quality of screening in primary care settings
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None